ArticleJournal of nanobiotechnology2026
pH-responsive virus-drug conjugates for targeted PD-L1 silencing and enhanced cancer immunotherapy.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Clinical efficacy of virotherapy is often limited by poor transduction and off-target effects. To overcome these hurdles, we engineered a multi-stage, pH-responsive virus-drug conjugate (VDC) for targeted, cancer immunotherapy. Our VDC comprises a recombinant adeno-associated virus serotype 2 (AAV2) encoding a programmed death-ligand 1 (PD-L1) short hairpin RNA (shRNA), which is chemically conjugated to the transduction-enhancing doxorubicin (Dox) with minimally cytotoxic dosage. This AAV2-Dox is shielded by a polyethylene glycol (PEG) layer attached via a pH-sensitive benzoic-imine linker, designed to be stable at physiological pH but cleavable within the acidic tumor microenvironment. AAV2-Dox produced an equivalent enhancement of transgene expression at a much lower concentration (0.005 µg mL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.